Monday, March 11, 2019 7:44:55 PM
The FDA does not regulate medical procedures performed by qualified and licensed doctors. CaverStem has the only clinically proven procedure to treat Erectile Dysfunction with adult stem cells in the US. CaverStem ONLY uses your own adult stem cells (not Embryonic stem cells) and they are not altered, manipulated or stored. Therefore, FDA does not object to these procedures.
CaverStem has been shown to be effective even in patients who do not respond to PDE5 inhibitors. CaverStem is safe.
Several doctors in the US have been vetted and signed and are now OPEN and treating patients (Doctors Gershman, Said, Bieri, Liu, Narayan, Niemczyk and Sanderson). Currently you can make an appointment any of those locations.
Dr. Antonini from Italy has also began treating patients in 2019 and we know patients were treated in Russia. CELZ reported that three more doctors are scheduled for training in March and April.
Over 50 domain names have been registered showing that MANY more doctors are being vetted or have shown interest. These includes MANY cities and states in the USA, and now we KNOW there are domains registered in Russia (PromoMed, Dr. Pushkar), Germany, France, Switzerland (Alto Uro, Dr. Bachmann) and Austria.
CaverStem has begun a series of mailer and email campaigns introducing the CaverStem procedure to licensed physicians in the areas of urology, sexual function and plastic surgery. This campaign which will be expanded on a monthly basis with follow up mailers and emails and calls from our sales representatives. It's the goal to reach out to a minimum of 2500 new physicians each month by these methods. CaverStem reported good replies from the January emails.
CaverStem has also increased its online presence on Social Media and by placing banner advertising on websites and search engines attracting the active male. They are currently scripting an advertising campaign in Los Angeles and will be the first city to expand into print and TV.
U.S. and international agreements have been reached for exclusive distribution rights for the FDA approved Generation 2 bone marrow harvest technology which has been used with multiple ED patients with excellent results.
Your DD will show that Dr. Gershman has been performing the procedure with EXCELLENT results…90% success rate, even in difficult patients.
A one-year trial has concluded and will PROVE the same results and you can watch it here; https://clinicaltrials.gov/ct2/show/NCT03699943?recrs=deghi&fund=2&lupd_s=09%2F27%2F2018&lupd_d=14 Please review this. You will be surprised by the patients ages IMO.
Revenue has now started, CMTH is cash flowing. Additional physicians are scheduled for training, patients are being treated and revenues are being generated and increasing each month. CMTH anticipates reaching financial self-sufficiency by revenues from sales in 2019.
CMTH has Institutional Investors now, slowing dilution and providing much better terms as CMTH completes the commercialization phase. The most recent notes that were issued in 2018 were renegotiated providing cash for operations.
CaverStem signed with PatientGain to redesigning the website for the anticipated HUGE volume of traffic CaverStem will generate. This has generated many calls to the vetted doctors.
CMTH has started commercializing and scheduling patients for the FemCelz procedure for the treatment of female sexual dysfunction using stem cells from the patient's own bone marrow. Many of the existing CaverStem affiliated physician's will also treat female patients for sexual function and we anticipate that they will be the leaders in progressing the FemCelz program.
CMTH anticipates acquiring the Virility Centers of America brand from affiliate company Creative Medical Health, Inc. in Q1 2019. The use of the Virility Centers brand is related to male and female wellness clinics, including sexual function (CaverStemTM and FemCelzTM), incontinence and infertility. This brand will compliment the CaverStem and FemCelz brands.
CaverStem and FemCelz are just TWO of SEVERAL patents held by CMTH. 4 NEW patents were applied for in 2018.
Gershman and Ichim have already successfully commercialized Medistem.
CaverStem, FemCelz, StemSpine & AmnioStem have all be TRADEMARKED
We KNOW CaverStem + StemSpine + AmnioStem = NASDAQ
PLEASE read the sticky posts seen when logging in to iHub through a browser!!
Recent CELZ News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 08:45:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 08:10:25 PM
- Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program • GlobeNewswire Inc. • 07/24/2024 01:00:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • GlobeNewswire Inc. • 07/10/2024 12:30:00 PM
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM